Vascular normalization: A real benefit?

Domenico Ribatti

Research output: Contribution to journalArticlepeer-review


It is well established that antibodies to vascular endothelial growth factor (VEGF) in combination with chemotherapeutic agents produce synergistic cytotoxicity in a range of cancer. In this review article, it has been analyzed whether the so-called vascular normalization of abnormal tumor blood vessels as an effect of VEGF inhibition in association with chemotherapeutic agents in the treatment of tumors produces a real benefit. Literature data show that the process of normalization of the structure of tumor blood vessels is not always accompanied with a real benefit. In fact as in the case of cerebral tumors, the process of normalization may induce a re-establishment of the low permeability characteristics of normal brain microvasculature, preventing the delivery of chemotherapeutics.

Original languageEnglish
Pages (from-to)275-278
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Issue number2
Publication statusPublished - Aug 2011


  • Angiogenesis
  • Antiangiogenesis
  • Chemotherapy
  • Vascular normalization
  • VEGF

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology


Dive into the research topics of 'Vascular normalization: A real benefit?'. Together they form a unique fingerprint.

Cite this